An Open Label Exploratory Study in Newly Diagnosed Prostate Cancer Patients
Status:
Completed
Trial end date:
2007-09-01
Target enrollment:
Participant gender:
Summary
Open-label exloratory pharmacodynamic and pharmacogenomic study to evaluate teh biologic
effects of 3 dose levels (1mg, 5 mg, and 15 mg) of temsirolimus administered orally once
daily for approximately 4 weeks (+/- 2 weeks) before prostatectomy